Scientists reveal how GRHL2 and progesterone receptor coordinate breast cell gene regulation

Inside breast cancer cells, two proteins have been quietly working together in ways scientists had not fully understood until now. A team of researchers has mapped out how GRHL2, a transcription factor, and the progesterone receptor coordinate their activity to control genes essential for breast development and function. The discovery emerged from a systematic hunt through the nuclear landscape of T47D breast cancer cells—cells that respond to the hormone progesterone.

The partnership begins before the hormone even arrives. Using a technique called rapid immunoprecipitation mass spectrometry, researchers identified progesterone receptor as one of GRHL2's most robust binding partners in cells starved of hormones. This was unexpected. The two proteins physically interact in the nucleus even without progesterone present, suggesting they form a pre-assembled complex waiting in the nucleoplasm. Validation experiments confirmed the interaction persists whether or not the hormone is added. Notably, GRHL2 binds preferentially to the full-length, transcriptionally active form of the receptor, not to a shorter variant.

When progesterone arrives—or in laboratory conditions, when researchers add a synthetic version called R5020—the partnership shifts into action. Mapping the DNA binding patterns of both proteins revealed they occupy overlapping sites at enhancers, the regulatory regions that sit far from genes but control their activity. Of 46,746 progesterone receptor binding sites identified across the genome, 6,335 overlapped with GRHL2 binding sites, representing 13.5 percent of receptor sites and 21.9 percent of GRHL2 sites. These shared regions corresponded to active enhancers marked by histone modifications indicating transcriptional engagement. The signal was strongest at the overlapping sites, though some binding occurred independently. Importantly, GRHL2 binding to chromatin was both strengthened and redistributed upon hormone stimulation, even though the protein's overall abundance increased only modestly.

To understand what genes this partnership controls, researchers created breast cancer cells with GRHL2 deliberately shut down and measured how gene expression changed in response to progesterone. They identified 298 genes regulated by both proteins—genes that showed altered expression at both four and twenty-four hours after hormone treatment, and whose response to the hormone depended on GRHL2's presence. Gene ontology analysis revealed these targets cluster in pathways governing signal transduction and cellular processes, with notable enrichment in developmental programs including gland development. Selected targets like IGFBP5 and TGFB2 were validated by quantitative PCR, confirming the RNA sequencing results.

But enhancers and promoters are often separated by vast stretches of DNA. The question remained: how do distant regulatory elements actually reach the genes they control? Using chromatin conformation capture data from prior studies, researchers traced physical three-dimensional loops connecting progesterone receptor and GRHL2 binding sites to the promoters of their target genes. Of the 298 co-regulated genes, 79 had promoters directly connected by chromatin loops to enhancer regions. These loops extended up to 500 kilobases, with most spanning 50 to 100 kilobases. At the anchors of these 146 loops, researchers found that 26 percent contained both GRHL2 and progesterone receptor binding, representing a twofold enrichment compared to the genome-wide average. Another 29 percent contained only progesterone receptor, while 11 percent contained only GRHL2. The remaining 21 percent lacked detectable binding by either protein, suggesting other transcriptional regulators participate in the regulatory architecture.

The researchers propose a model for how this system operates. In the absence of hormone, GRHL2 and progesterone receptor exist as a nuclear complex but do not stably bind chromatin. Their target enhancers and promoters remain spatially separated in three-dimensional space. Upon progesterone stimulation, the hormone-activated receptor recruits GRHL2 to enhancers, and protein complexes including cohesin—a ring-shaped protein that holds DNA loops together—stabilize long-range interactions. These loops bring distal enhancers into contact with target gene promoters, enabling coordinated transcriptional activation. The model accommodates multiple regulatory architectures: some genes are controlled by enhancers bound by both proteins, others by distinct enhancers each bound by one protein, and still others by combinations involving additional transcriptional cofactors.

To assess clinical relevance, researchers examined 1,980 primary breast tumors from the METABRIC cohort. They constructed a composite signature score from the 298 co-regulated genes and found that high signature expression correlated with significantly reduced overall survival. This association held in multivariable analysis adjusting for age and tumor stage. Counterintuitively, progesterone receptor-positive tumors had lower signature scores than receptor-negative tumors, suggesting the prognostic impact of the signature operates independently of receptor status. The authors acknowledge this analysis is exploratory and that functional progesterone signaling in primary tumors is difficult to assess directly, warranting further validation in stratified patient populations.